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sevier Taiwan LLC. Open access under CSummary Background/aims: Transcatheter arterial chemoembolization (TACE) is a main
therapy for patients with intermediate-stage hepatocellular carcinoma (HCC). The purpose
of our study was to determine the risk factors for 1-year mortality in patients treated solely
with TACE.
Methods: A total of 123 patients with intermediate-stage HCC treated solely with TACE were
recruited from Ren-ai Branch, Taipei City hospital during the period from January 1998 to June
2013. Baseline characteristics and factors associated with 1-year mortality were analyzed.
Results: There were 94 men (76.4%) and 29 women (23.6%) among 123 newly diagnosed
intermediate-stage HCC patients treated solely with TACE. The mean age was 63  11 years
(range, 31e92 years). The 1e5-year overall cumulative survival rates were 65.9%, 46%,
33.2%, 22%, and 18.4% [median: 23 months, 95% confidence interval (CI): 16.4e29.6 months],
respectively. Of these, 42 (34.1%) and 81 (65.9%) patients had survival time shorter (Group 1)
and longer (Group 2) than 1 year, respectively. There were no significant differences in sex,
age, hepatitis B virus/hepatitis C virus positive rate and tumor number between Group 1
and Group 2 patients. Compared to Group 2, Group 1 patients had a significantly larger mean
maximum tumor size (6.8  3.2 cm vs. 5.3  3.1 cm, p Z 0.024), lower serum albumin level
(3.4  0.45 g/dL vs. 3.6  0.46 g/dL, pZ 0.011), higher serum bilirubin level (1.52  1.07 mg/
dL vs. 1.07  0.59 mg/dL, pZ 0.023), higher ratio of serum alpha-fetoprotein (AFP) > 400 ng/t of Gastroenterology, Ren-Ai Branch, Taipei City Hospital, Number 10, Section 4, Ren-Ai Road,
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One-year mortality in intermediate-stage HCC treated solely with TACE 127mL (52.4% vs. 24.7%, pZ 0.003), and higher ratio of Child-Turcotte-Pugh (CTP) class B cirrhosis
(26.2% vs. 6.2%, pZ 0.003). Multivariate analysis revealed that AFP level > 400 ng/mL [hazard
ratio (HR): 2.663, 95% CI: 1.143e6.205, p Z 0.023], CTP class B cirrhosis (HR: 4.69, 95% CI:
1.399e15.715, p Z 0.012) and tumor size (HR: 1.153 for each 1 cm increase, 95% CI: 1.015
e1.310, p Z 0.029) were independently associated with 1-year mortality.
Conclusion: One-year mortality in patients with intermediate-stage HCC treated solely with
TACE is not uncommon. High serum AFP level (> 400 ng/mL), CTP class B cirrhosis, and tumor
size are independent risk factors for 1-year mortality in those patients.
Copyright ª 2014, The Gastroenterological Society of Taiwan and The Digestive Endoscopy So-
ciety of Taiwan. Published by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.Introduction
Hepatocellular carcinoma (HCC) is the leading cause of
cancer-related deaths in the world [1]. Although periodic
screening in a definable high risk population would benefit in
detecting HCC in an early curable stage and yield a long-term
survival [2], the worldwide 5-year survival rate of HCC only
slightly increased from 5% to 15% over the past 2 decades [3].
The major causes of unsatisfactory prognosis of HCC include
that curative treatment is possible in only a small percentage
of patients [4] and the heterogeneous nature of HCC affects
treatment outcome. Cumulative evidence has suggested
that the stage of HCC and efficacy of optimal treatment may
be used to predict the survival rate at the time of HCC diag-
nosis [5].Currently, theAmericanAssociation for the Studyof
Liver Diseases (AASLD) guidelines, a revised version of the
Barcelona Clinic Liver Cancer (BCLC) staging system by
AASLD, are most widely used in HCC management [5,6]. Ac-
cording to the guidelines, transcatheter arterial chemo-
embolization (TACE) has been recognized as an effective
option for those with intermediate-stage HCC (BCLC stage B)
[5e7]. TACE has been considered a palliative treatment for
unresectable HCC. However, cumulative meta-analysis of all
published randomized, controlled trials indicates that pa-
tient survival is significantly improved after TACE [8]. A
nationwide, multicenter study from four medical centers in
Taiwan reported that the 1-, 3-, and 5-year survival rates for
unresectable HCC patients who underwent TACE alone were
significantly higher than for thosewho underwent supportive
treatment (60.2%, 39.3%, and 11.5% vs. 37.3%, 17.6%, and 2%,
respectively) [9]. Nonetheless, the improvement in survival
in treated patients is not satisfactory, and ranges from20% to
60% at 2 years [10]. It is therefore important to clarify
the risk factors that affect short-term mortality in HCC
patients treated with TACE. The purpose of our study
was to determine the risk factors for 1-year mortality in
intermediate-stage HCC patients treated solely with TACE.Materials and methods
Patients
A total of 123 newly diagnosed intermediate-stage HCC
patients treated solely with TACE were retrospectively
enrolled from Ren-ai Branch, Taipei City Hospital, Taiwanbetween January 1998 and June 2013. The severity of
cirrhosis was assessed by the Child-Turcotte-Pugh (CTP)
score [11]. The diagnosis of HCC was histologically
confirmed in 74 (60.2%) patients. The remaining 49 (39.8%)
patients were confirmed by typical imaging studies, such as
enhanced computed tomography (CT) or magnetic reso-
nance imaging (MRI). Typical HCC exhibited arterial
enhancement and portal venous washout on multiphasic CT
or MRI [5,6]. According to the BCLC staging system, inter-
mediate-stage HCC was defined as CTP class A and B
cirrhotic patients with large or multifocal HCC who do not
have cancer related symptoms and do not have macro-
vascular invasion or extrahepatic spread [7]. This study
protocol was approved by the Institutional Review Board of
Taipei City Hospital.
Biochemical and serological testing
The biochemical tests were measured by using routine
automated methods. The Hepatitis B surface antigen
(HBsAg) and anti-hepatitis C virus (HCV) were assayed using
commercial kits (General Biological HBsAg radioimmuno-
assay, General Biological Cooperation, Hsinchu, Taiwan.
HCV enzyme immunoassay (EIA) II; Abbot Laboratories,
North Chicago, IL, USA).
Procedure of TACE
TACE was performed in a dedicated angiography suite
DFP8000D (Toshiba Medical Systems, Otawara, Japan) with
4Fr J-Curve catheters (Terumo Medical Corporation, Tokyo,
Japan) inserted via right external femoral artery puncture,
guided by a matching mandrel (Terumo Medical Corpora-
tion). The J-Curve catheter tip was placed in the celiac axis
orifice and one set of digital subtraction angiography was
performed with a bolus of 21 mL of nonionic iodinated
contrast medium Iopamiro 370 (Bracco Imaging, Milan,
Italy) injected by ProVis power injector (Medrad Inc.,
Warrendale, PA, USA) at 3mL/second. For patients with S5
or S6 tumors, which might draw their tumor vessels from
superior mesenteric branches, digitally-subtracted superior
mesenteric angiography was also performed using exactly
the same parameters.
If the tumor stains and the supplying vessels were not
well demonstrated by the above angiograms, further
superselective angiograms were performed, including
Table 1 Demographic and clinical characteristics of 123
patients with intermediate-stage hepatocellular carcinoma
treated solely with transcatheter arterial chemo-
embolization stratified by 1-year mortality.
Characteristics Group 1a
(n Z 42)
Group 2b
(n Z 81)
p
Sex
Male 29 (69) 65 (80.2) 0.184
Female 13 (31) 16 (19.8)
Mean age (y) 61.6  12.1 64  10.9 0.272
 60 18 (42.9) 30 (37) 0.563
> 60 24 (57.1) 51 (63)
Etiology
HBV infection 26 (61.9) 37 (45.7) 0.302c
HCV infection 12 (28.6) 27 (33.3)
HBV/HCV coinfection 0 5 (6.2)
Missing data 4 (9.5) 12 (14.8)
Child-Turcotte-Pugh class
A 31 (73.8) 76 (93.8) 0.003
B 11 (26.2) 5 (6.2)
Laboratory data
Albumin (g/dL) 3.4  0.45 3.6  0.46 0.011
Total bilirubin (mg/dL) 1.52  1.07 1.07  0.59 0.023
ALT (U/L) 94  136 77  58 0.312
PT (s) 12.9  1.5 12.4  1.8 0.213
AFP (ng/mL)
 400 20 (47.6) 61 (75.3) 0.003
> 400 22 (52.4) 20 (24.7)
Maximum tumor
size in cm (range)
6.8  3.2
(2e15)
5.3  3.1
(1.0e16.0)
0.024
Number of tumors
1 11 (26.2) 9 (11.1) 0.104
2e3 15 (35.7) 35 (43.2)
> 3 16 (38.1) 37 (45.7)
DM
Yes 12 (28.6) 27 (33.3) 0.718
No 30 (71.4) 54 (66.7)
Data are presented as n (%) or mean  SD, unless otherwise
indicated.
AFP Z alpha-fetoprotein; ALT Z alanine aminotransferase;
DM Z diabetes mellitus; HBV Z hepatitis B virus;
HCV Z hepatitis C virus; PT Z prothrombin time.
a Group 1: patients with 1-year mortality.
b Group 2: patients with survival time longer than 1 year.
c HBV infection vs. HCV infection.
128 C.-L. Lin et al.angiograms of common hepatic artery, proper hepatic ar-
tery, right or left hepatic arteries, and sometimes even
smaller segmental branches. Only after identifying ex-
pected tumor stains and vessels was embolization per-
formed from an appropriate site, which was usually a
proper hepatic artery for multiple bilateral tumors, and
right or left hepatic arteries for unilateral tumors. Occa-
sionally embolization was performed more superselectively
to avoid concomitant embolization of the right gastric or
cystic arteries, as well as to minimize collateral damage in a
patient with poor liver reserve. Superselection was usually
performed with additional coaxial microcatheters and guide
wires, usually ranging from 2.5Fr to 3Fr in the outer diam-
eter and with malleable mandrel tips. The embolization
agents were ethiodized oil Lipiodol (Guerbet, Villepinte,
France) and absorbable gelatin sponge Surgifoam (Ethicon,
Somerville, NJ, USA), and the chemotherapy agents were
mitomycin and doxorubicin. The dosage of Lipiodol and
gelatin sponge was based on sufficient slowing of arterial
flow as demonstrated by fluoroscopy, typical dose range
3e15 mL of Lipiodol. Exact dose calculation of gelatin
sponge was not possible as it is usually shredded from a
larger piece. The dosages of mitomycin and doxorubicin
were determined by patient weight; the typical dose of
mitomycin was 4e8 mg and for doxorubicin was 20e30 mg.
The presence of viable tumor was confirmed by multiphasic
CT or MRI, 1e2 months after TACE. TACE was repeated with
an interval of 3 months when viable tumor was found.
Statistical analysis
Data were analyzed by Chi-square test, Fisher’s exact test,
Student t test, and logistic regression where appropriate.
Overall survival was measured from the day of HCC diag-
nosis and patient survival was confirmed through June 2013.
Cumulative survival was calculated according to the
Kaplan-Meier method. The association of potential risk
factors with 1-year mortality was determined by univariate
and multivariate logistic regression. All tests were two-
tailed and p < 0.05 was considered statistically significant.
Results
Baseline clinical characteristics of the 123 intermediate-
stage HCC patients treated solely with TACE are shown in
Table 1. There were 94 men (76.4%) and 29 women (23.6%).
The mean age was 63  11 years (range: 31e92 years).
Among them, 20 patients (16.3%) had solitary lesions, 27
patients (21.9%) had two tumors, and 76 patients (61.8%)
had more than three tumors. The mean of maximum tumor
size was 5.8  3.2 cm (range: 1e16 cm). The dominant
etiologies were hepatitis B virus (HBV) infection (63/123,
51.2%) and HCV infection (39/123, 37.1%). Regarding the
liver function reserve, 107 patients (87%) were classified as
CTP class A cirrhosis and 16 patients (13%) had CTP class B
cirrhosis. Eighty-one and 42 patients (65.9% and 34.1%) had
serum alpha-fetoprotein (AFP) levels  400 ng/mL and
> 400 ng/mL, respectively. The mean follow-up duration
was 22 (range: 1e104) months. The 1e5-year overall cu-
mulative survival rates were 65.9%, 46%, 33.2%, 22%, and
18.4% [median: 23 months, 95% confidence interval (CI):16.4e29.6 months], respectively (Fig. 1). The baseline
characteristics of the patients stratified by 1-year survival
are shown in Table 1. There were 42 (34.1%) and 81 (65.9%)
patients with survival time < 1 year (Group 1) and > 1 year
(Group 2), respectively. There were no significant differ-
ences in terms of sex, age, prevalence of HBV/HCV infec-
tion, prevalence of diabetes mellitus, and tumor number
between Group 1 and Group 2 patients. Compared to Group
2 patients, Group 1 patients had a significantly larger mean
of maximum tumor size (6.8  3.2 cm vs. 5.3  3.1 cm,
pZ 0.024), lower serum albumin level (3.4  0.45 g/dL vs.
3.6  0.46 g/dL, p Z 0.011), higher serum total bilirubin
level (1.52  1.07 mg/dL vs. 1.07  0.59 mg/dL,
p Z 0.023), higher ratio of AFP level > 400 ng/mL (52.4%
Figure 1 The cumulative survival curve of 123 intermediate-
stage hepatocellular carcinoma patients treated solely with
transcatheter arterial chemoembolization.
One-year mortality in intermediate-stage HCC treated solely with TACE 129vs. 24.7%, p Z 0.003), and higher ratio of CTP class B
cirrhosis (26.2% vs. 6.2%, pZ 0.003). The causes of death of
Group 1 patients included uncontrolled HCC (25 patients),
hepatic failure (15 patients), and esophageal variceal
bleeding (2 patients).
Results of logistic regression for risk factors against 1-
year mortality are shown in Table 2. AFP level > 400 ng/mL
[hazard ratio (HR):3.355, 95% CI:1.525e7.381, p Z 0.003],
CTP class B cirrhosis (HR:5.394, 95% CI:1.731e16.808,
p Z 0.004), and tumor size (HR:1.145 for each 1 cm in-
crease, 95% CI:1.015e1.291, p Z 0.028) were significantly
associated with 1-year mortality in univariate logistic
regression analysis. However, only AFP level > 400 ng/mL
(HR: 2.663, 95% CI:1.143e6.205, p Z 0.023), CTP class BTable 2 Univariate and multivariate analyses of factors associa
stage hepatocellular carcinoma treated solely with transcatheter
Factor Univariate
Hazard ratio (95% CI)
Sex
Male 1
Female 1.821 (0.776e4.272)
Age
 60 y 1
> 60 y 0.784 (0.367e1.676)
AFP
 400 1
> 400 3.355 (1.525e7.381)
Etiology
B 1
C 0.632 (0.272e1.476)
Child-Turcotte-Pugh
A 1
B 5.394 (1.731e16.808)
Tumor size
Increase 1 cm 1.145 (1.015e1.291)
AFP Z alpha-fetoprotein; CI Z confidence interval.cirrhosis (HR: 4.69, 95% CI:1.399e15.715, p Z 0.012), and
tumor size (HR: 1.153 for each 1 cm increase, 95%
CI:1.015e1.310, pZ 0.029) were independently associated
with 1-year mortality in the subsequent multivariate logis-
tic regression analysis.
A comparison of the long-term survival of patients
stratified by CTP classification and serum AFP levels is
shown in Fig. 2. Patients with CTP class A cirrhosis had
significantly higher 1-, 2-, and 3-year cumulative survival
rates compared with those who had CTP class B cirrhosis
(71%, 50.0%, 38.2% vs. 31.2%, 15.6%, 0%, respectively,
p < 0.001). Similarly, patients with serum AFP levels
 400 ng/mL had significantly higher 1-, 2-, and 3-year
cumulative survival rates than those with serum AFP
levels > 400 ng/mL (75.3%, 51.9%, 39.9% vs. 47.6%, 34.4%,
21.2%, respectively, p Z 0.039).Discussion
The major reasons for poor prognosis of HCC include the
heterogeneous nature of HCC and the difficulty in making
the most appropriate treatment planning decision for an
individual patient. Therefore, staging-related treatment
planning is important for predicting prognosis and guiding
the therapeutic approach. In addition to BCLC [12], current
HCC staging systems include the Okuda system [13], the
Cancer of the Liver Italian Program (CLIP) score [14], the
Japan Integrated Scoring system [15], and the tumor-node-
metastasis (TNM) staging system [16]. Among these, the
BCLC staging system and recommended treatment strategy
(AASLD guideline), which is linked to the underlying liver
function and the extension of the tumor, is the most widely
used in the management of HCC [5,6]. According to AASLD
guidelines, patients with intermediate-stage HCC are
asymptomatic with multinodular tumors, but withoutted with 1-year mortality in 123 patients with intermediate-
arterial chemoembolization.
Multivariate
p Hazard ratio (95% CI) p
0.168
0.531
0.003 0.023
1
2.663 (1.143e6.205)
0.288
0.004 0.012
1
4.69 (1.399e15.715)
0.028 0.029
1.153 (1.015e1.310)
Figure 2 Comparison of cumulative long-term survival curves
of intermediate-stage hepatocellular carcinoma patients
treated solely with transcatheter arterial chemoembolization
according to (A) Child-Turcotte-Pugh cirrhosis and (B) serum
alpha-fetoprotein (AFP) levels.
130 C.-L. Lin et al.vascular invasion or extrahepatic metastasis, and are
eligible for TACE.
TACE is the most widely used palliative treatment for
patients with unresectable HCC [17]. A previous meta-
analysis, including seven randomized trials and 545 pa-
tients, revealed that TACE improved the 2-year survival of
unresectable HCC patients compared with supportive
treatment. However, the 1-year survival varies from 24% to
82% [18]. Therefore, the selection of ideal candidates for
TACE should improve the long-term survival effect of
the treatment. In our retrospective study, records of 123
intermediate-stage HCC patients treated solely with TACE
were analyzed and assessed with survival as a primary
endpoint. Our study showed that the 1-year mortality still
remains at a disappointing 34.1%. Importantly, CTP class B
cirrhosis was associated with 1-year mortality. Furtherlong-term survival analysis revealed that patients with CTP
class A cirrhosis had a significantly higher cumulative sur-
vival rate than those with CTP class B cirrhosis. CTP clas-
sification was already a known independent prognostic
factor for HCC [19e21]. In addition, CTP classification has
been incorporated to current prognostic staging systems
(CLIP and BCLC staging systems) [12,14]. According to the
BCLC staging system, intermediate-stage HCC includes both
CTP class A and B patients; the discriminating survival of
patients in intermediate-stage HCC is expected. Our results
indicated that individual HCC patients in a single BCLC
stage have inconsistent responses to specific therapy.
The prognostic role of baseline AFP values for HCC pa-
tients has been confirmed in multiple studies and incorpo-
rated in the CLIP system [14,22]. Furthermore, serum AFP
level is associated with poor tumor biological behavior of
HCC, such as tumor multiplicity, low grade differentiation
and carcinoma cell embolus, as well as moderate/severe
cirrhosis [23]. Recent studies of patients with BCLC stage A
and B HCC revealed that serum AFP level was an indepen-
dent predictor of worse survival [24,25]. Consistent with
previous studies, we found that the serum AFP level was
significantly associated with 1-year mortality of interme-
diate-stage HCC patients treated solely with TACE. Taken
together, incorporation of AFP level to current HCC staging
systems in evaluating prognosis should be considered in
clinical practice.
The treatment effects of TACE in unresectable HCC
include local tumor control and prolonged survival [26].
However, TACE only allows complete local tumor control of
25e35% [27]. Furthermore, TACE may induce hepatic
function deterioration especially in cirrhotic patients and
lead to an increased incidence of liver failure [28,29]. For
this reason, uncontrolled HCC and hepatic failure were
possibly the causes of death in two-thirds of our patients.
There are several limitations of this study. First, as a
retrospective study design, data collection depends on the
availability and accuracy of the medical record. Thus, the
existence of patient selection bias should be considered. In
addition, the frequency of TACE administration for indi-
vidual patients varies in our study, which was influenced by
tumor progression and the severity of cirrhosis during the
follow-up period. Therefore, large cohort studies are
needed to further evaluate the optimum TACE treatment
strategy.
In conclusion, the treatment strategies of HCC are well
developed during the past 2 decades. Based on the BCLC
staging system, TACE is the recommended treatment for
patients with intermediate-stage HCC. Unfortunately, the
long-term effects of TACE still remain unsatisfactory. The
1-year mortality in patients with intermediate-stage HCC
treated solely with TACE is common. High serum AFP level
(> 400 ng/mL) and CTP class B cirrhosis are independent
risk factors for 1-year mortality in those patients. Careful
patient selection is the key point to improve the early and
long-term results of TACE in patients with intermediate-
stage HCC.Conflicts of interest
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